Veranstaltung an

HbA1c and CRP point-of-care testing as important tools in managing patients with diabetes and patients with COVID-19


Join our panel of experts from around the world for this compelling event presenting a view from the front line on the management of diabetes patients and comorbidities in the context of COVID-19.

With telehealth and remote treatment on the rise, a unique and international group of experts will analyse how rapid point-of-care testing may benefit patients with diabetes in the COVID-19 healthcare landscape and beyond.

Screening and monitoring of diabetes and cardiovascular patients is even more critical nowadays. According to the World Health Organisation, individuals may be more susceptible to severe COVID-19 and death if they have a noncommunicable disease, such as diabetes, high blood pressure, cardiac disease, kidney disease, chronic lung disease, cerebrovascular disease or cancer. [1] Diabetes has not yet been shown to increase the likelihood of SARS-CoV-2 infection, but progression to severe illness is more likely in people with diabetes.2 The frequency of diabetes among COVID-19 patients requiring hospitalisation or intensive care is two to three times higher than in the overall population, and mortality rates in those with diabetes are also higher. [2] [3] [4] [5] [6] [7] [8].

Point-of-care testing for HbA1c aids in achieving improved glycaemic control with just one office visit. [9] [10] [11] [12]

In this educational event, the group of experts will share new strategies for the management of diabetes and comorbidities and how countries around the world are successfully adopting rapid HbA1c and lipid pointof-care testing for the continued remote management of diabetes and cardiovascular patients during COVID-19 and beyond.

Die dargestellten Ansichten und Meinungen stammen ausschließlich von den Autoren. Der in diesem Webcast enthaltene Inhalt ist nur für Informations-/Bildungszwecke bestimmt.

  1. World Health Organisation. Clinical management of COVID-19: Interim guidance, 27 May 2020. WHO/2019-nCoV/clinical/2020.5.
  2. Riddle M, Buse JB, Franks PW, et al. COVID-19 in People With Diabetes: Urgently needed Lessons From Early Reports. Diabetes Care. Published online May 14, 2020.
  3. Centers for Disease Control and Prevention. COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. Morbidity and Mortality Weekly Report. April 3, 2020;69(13):382-386.
  4. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalised With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-2059.
  5. Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalised in the United States. J Diabetes Sci Technol. Published online May 9, 2020.
  6. Palmieri L, Andrianou X, Barbariol P, et al. COVID-19 Surveillance Group. Characteristics of SARS-CoV-2 patients dying in Italy. Report based on available data on April 20, 2020. EpiCentro. Accessed June 5, 2020. bollettino/Report-COVID-2019_20_April_2020.pdf
  7. Chen Y, Yang D, Cheng B. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose Lowering Medication. Diabetes Care. Published online May 14, 2020.
  8. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New Engl J Med. 2020;382:1708-20.
  9. Lian J, Liang Y. Curr Med Res & Op. 2014;30(11):2233-2240.
  10. Egbunike V, Gerard S. Diabetes Educator. 2013;39(1):66-73.
  11. Lee-Lewandrowski L, Yeh S, Baron J, Crocker JB, Lewandrowski K. Clin Chim Acta. 2017;473:71-74.
  12. Crocker JB, Lee-Lewandrowski E, Lewandrowski N, Baron J, Gregory K, Lewandrowski K. AJCP. 2014;142:640-646

© 2022 Abbott. Alle Rechte vorbehalten. Alle genannten Marken sind Marken der Abbott-Unternehmensgruppe oder ihrer jeweiligen Eigentümer. Alle angezeigten Fotos dienen nur zur Veranschaulichung. Jede auf solchen Fotos abgebildete Person ist ein Model. Produkte nur in ausgewählten Märkten erhältlich. COL-03458 V1.0 05.21